DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Centers for Disease Control and Prevention.
Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection.
MMWR 2003;
52: 735-739
Access:
We do not assume any responsibility for the contents of the web pages of other providers.